Loading…
← CockpitCompetitor Analysis › 1672.HK Ascletis Pharma, Inc.Open in the cockpit ↗

Ascletis Pharma, Inc.1672.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology

Chinese biotech developing antiviral drugs (hepatitis, HIV) and newer obesity/metabolic and oncology drug candidates.

Momentum laggard 4
Mkt cap
$571M
US dollars, full cap
Free float
28%
of shares outstanding
$/day
$1.32M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.2%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · HKDHK$4.37
1D+0.1%
1W-8.5%
1M-23.7%
3M-55.5%
6M-71.8%
YTD-61.6%
1Y-57.8%
ATR %10.4%
52w lowhigh78.0% off high

What Ascletis Pharma does

Chinese biotech developing antiviral drugs (hepatitis, HIV) and newer obesity/metabolic and oncology drug candidates.

Income so far is small next to development spending, which is funded by investor money and out-licensing deals. Success rests on its obesity candidates reaching late-stage trials.

Products and services

  • Hepatitis C antivirals
  • Obesity/GLP-1 pipeline
  • Oncology pipeline
  • HIV antivirals

Customers

  • Hospitals & patients in China
  • Global licensing partners

Where it sits in the supply chain

  • Biopharmaceuticals
  • Drug discovery & clinical development
  • Commercialization in China

What could go right

  • Obesity drug market growth in China
  • Pipeline licensing deals

What could go wrong

  • Clinical trial risk
  • Competition from global GLP-1 leaders

Moat: narrow (IP / patents). First-mover China antiviral approvals and a differentiated oral obesity pipeline, still early-stage overall.

Headquarters: Hangzhou, China · Founded: 2013 · Employees: 202

Named competitors

Ascletis Pharma at a glance

Size Ascletis Pharma (1672.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $571M, the 717th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.37 on 18 Nov 2026.

Performance Over six months the shares fell 71.8%, against -17.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue fell 59.4% over the last twelve months (peer median +9.1%); the operating margin is -71,976.2% (peer median -10.7%).

Valuation It trades at 1,794.8× enterprise value to sales against a peer median of 3.4× (most expensive of 16).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 821672.HK 29
Six months, rebased to 100: Ascletis Pharma against the median of its 20 peers (local-currency closes).

Ascletis Pharma financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.04MHK$2.20MHK$1.39MHK$62.5MHK$62.9M
Revenue growth—+58%-98%-1%—
Gross profit-HK$18.3M-HK$18.5M-HK$21.7MHK$7.97M-HK$58.3M
EBITDA-HK$727M-HK$506M-HK$415M-HK$320M-HK$365M
Net income-HK$662M-HK$390M-HK$326M-HK$160M-HK$366M
Free cash flow-HK$566M-HK$368M-HK$239M-HK$166M-HK$174M
Capital expenditureHK$2.48MHK$2.14MHK$2.33MHK$21.2MHK$16.7M
Total debtn/aHK$5.75MHK$8.12MHK$9.27MHK$4.76M

Quarterly statements and history in the cockpit →

Ascletis Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-50%0%+50%+100%GNFTFDMT300404SANA300871WVECLYM1521SRZN603387JANXGERN1672.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Ascletis Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+20,000%+40,000%+60,000%+80,000%0×1,000×GNFTFDMT3004041672.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ascletis Pharma is the large dot.

Ascletis Pharma competitors and peer comparison

Head to head with its named competitors (1672.HK vs 1801.HK vs 600276.SS vs LLY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Ascletis Pharma 1672.HK$571M-72%-59%-71,976%1,794.8×n/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%8.0×13.4%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%

How Ascletis Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ascletis Pharma against its 20 peers (data as of 18 Nov 2026)
Measure1672.HKPeer medianRank in peer set
1-month return-23.7%-12.2%3rd lowest of 21
6-month return-71.8%-17.1%lowest of 19
Distance from 52-week high-78.0%-49.8%2nd lowest of 21
Revenue growth (TTM)-59.4%+9.1%lowest of 17
Operating margin-71,976.2%-10.7%lowest of 17
EV / Sales1,794.8×3.4×most expensive of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%1,794.8×n/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%11.0×39.8%+143.5%
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%3.2×n/an/a
Boji Medical Technology 300404.SZChina$561M-6%+32%4%3.4×31.9%+27.2%
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%2.3×n/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%26.8×n/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%2.2×n/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Frontage 1521.HKHong Kong$542M+113%+10%8%2.3×14.3%+15.4%
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a

Questions

Who are Ascletis Pharma's main competitors?
Named competitors: Innovent Biologics (1801.HK), Hengrui Pharmaceuticals (600276.SS), Eli Lilly (LLY). The cockpit's measured peer set (industry) also includes Genfit (GNFT.PA), 4D Molecular Therapeutics (FDMT), Boji Medical Technology (300404.SZ), Sana Biotechnology (SANA), Hvsen Biotechnology (300871.SZ), Alebund Pharmaceuticals (Jiangsu) (9637.HK).
Is Ascletis Pharma expensive compared with its peers?
On ev / sales it trades at 1,794.8× against a peer median of 3.4×, most expensive of 16 in its peer set.
How has Ascletis Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -71.8% against -17.1% for the median peer; over one year -57.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.